U.S. Senate panel postpones Mylan hearing

WASHINGTON (Reuters) - The U.S. Senate Judiciary Committee on Monday postponed a hearing planned for next week to discuss Mylan NV's pending $465 million settlement to resolve charges that it underpaid government healthcare programs by misclassifying its EpiPen emergency allergy treatment.